ArticleJournal of molecular histology2025
Atorvastatin improves long-term memory by reducing amyloid-β formation and neuronal damage in STZ-induced diabetic rats.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diabetes mellitus is associated with decline in cognitive function and changes in brain structure. Statins have received increasing attention to be used as neuroprotective drug. We examined the neuroprotective effects of atorvastatin on neuropathological alterations such as learning and memory performance, the amyloid-β formation, and expression of nitric oxide synthases (NOSs) in hippocampus of streptozotocin (STZ)-induced diabetic rats. Adult male Wistar rats were divided into four groups; The normal control group, STZ-induced diabetes group, STZ-induced diabetic rats followed by treatment with atorvastatin group and normal rats treated with atorvastatin. The passive avoidance test was used to evaluate the learning and memory status of animals. Blood and hippocampus samples were obtained for biochemical and histological analysis. The expressions of nitric oxide synthases were immunohistochemically detected, and histopathological changes of amyloid beta were examined using Congo red stain in CA1 region of hippocampus. Count of congo red positive cells in CA1 region increased in diabetic rats, however atorvastatin treatment decreased it. Amyloid-β levels and S100B levels in the hippocampus and plasma increased in diabetic rats, atorvastatin treatment decreased. Total nitrite-nitrate levels increased, while iNOS expression decreased in the CA1 area of hippocampus in atorvastatin treated diabetic rats, eNOS and nNOS expression increased. The retention latency times of diabetes group decreased, however atorvastatin treatment to diabetic rats prolonged at the 48th hour and 72nd hour. Atorvastatin improved the long-term memory by suppressing the formation of amyloid-β, increasing eNOS and nNOS protecting the blood brain barrier in diabetic rats.
Indexed as
Identifiers
40897827What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.